Touchstone
Last syncNov 1, 2026, 6:55 PM ET

RGEN

Repligen Corp Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$176.94Close $10.0BMarket cap $102.87 – $194.5752-week range Late-januaryNext report · estimated

Highlights

Strengths

  • Leading the market RS 82 · stronger than 82% of stocks over 12 months

Cautions

  • Trend not confirmed 7 of 8 conditions · under the 50-day
  • Earnings shrinking EPS −358% year on year

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Oct 30, 2026
Off 12-month high 9%
1wk 0.0% price change
1mo down 8.0% price change
12-month return up 22% market up 11% · its own up 8%
F-score 6 / 9 Mixed
Altman Z 8.02 Low risk
P/E 203.8× price / earnings
PEG — P/E / EPS growth
P/B 4.7× price / book
Earnings yield up 0.6% EBIT / enterprise value
Cheaper than 31% of the market · expensive
Revenue growth up 16% year on year
EPS growth down 358% latest quarter · -291 pts
Sales growth up 11% latest quarter · -1 pts
ROE up 2% return on equity
Free cash margin up 13% $93.9M FCF
D/E 0.26 long-term debt / equity
Net debt / EBITDA -0.2× net cash
Interest cover 2.4×EBIT / interest
Piotroski tests
  • took on more long-term debt
  • short-term liquidity weakened
  • issued more shares
  • profitable on its assets
  • generating cash from operations
  • profitability improving
  • profits backed by cash
  • gross margin widened
  • assets working harder

Repair signals

  • Gross margin 43.3% → 52.3%

Trade setup

ATR% 5.3% $9.35 a day · 2×ATR $158.24
RS 82 / 99 vs the universe
Trend 7 / 8 under the 50-day
Relative volume 3.8× vs 50-day average
Up/down volume 0.99 50 sessions
Implied move — no scheduled report
Trend template · 7 of 8
  • Price above the 50-day average: fails

Screen verdict

Did not qualify for any screen.

Warning signs

none flagged
  • No restatement or impairment
  • Equity positive
  • Interest covered
  • No material dilution
  • Profits tracking cash
  • Margins and revenue not shrinking
Last reported Oct 27, 2026
Results reaction Oct 27, 2026+2% vs market2 sessions after results

Financials

6 fiscal years · from filings
Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $738.3M +16% on FY2024
$0 $1B FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · $366.3M FY2021 · $670.5M FY2022 · $801.5M FY2023 · $632.4M FY2024 · $634.4M FY2025 · $738.3M
Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology $48.9M back to a profit
-$50M $0 $200M FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · $59.9M FY2021 · $128.3M FY2022 · $186.0M FY2023 · $35.6M FY2024 · -$25.5M FY2025 · $48.9M
Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology $93.9M -37% on FY2024
$0 $200M FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · $40.2M FY2021 · $51.9M FY2022 · $87.2M FY2023 · $77.7M FY2024 · $149.7M FY2025 · $93.9M
Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology
  • Gross 52%
  • Net 7%
  • Free cash 13%
0% 100% FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · Gross 57% · Net 16% · Free cash 11% FY2021 · Gross 58% · Net 19% · Free cash 8% FY2022 · Gross 57% · Net 23% · Free cash 11% FY2023 · Gross 44% · Net 6% · Free cash 12% FY2024 · Gross 43% · Net -4% · Free cash 24% FY2025 · Gross 52% · Net 7% · Free cash 13%
Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology $23.8M net cash
  • Cash
  • Long-term debt
$0 $1B FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · Cash $717.3M · Long-term debt $287.5M FY2021 · Cash $603.8M FY2022 · Cash $523.5M FY2023 · Cash $751.3M FY2024 · Cash $757.4M · Long-term debt $525.6M FY2025 · Cash $566.0M · Long-term debt $542.2M
Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 56.33m +2.9% since FY2020
56.33m 54.76m FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · 54.76m FY2021 · 55.32m FY2022 · 55.56m FY2023 · 55.77m FY2024 · 56.09m FY2025 · 56.33m
  FY2020Dec 31, 2020 FY2021Dec 31, 2021 FY2022Dec 31, 2022 FY2023Dec 31, 2023 FY2024Dec 31, 2024 FY2025Dec 31, 2025
Revenue $366.3M $670.5M $801.5M $632.4M $634.4M $738.3M
Gross margin 57% 58% 57% 44% 43% 52%
Operating income $69.8M $167.2M $224.7M $47.7M -$35.1M $55.2M
Net income $59.9M $128.3M $186.0M $35.6M -$25.5M $48.9M
Net margin 16% 19% 23% 6% -4% 7%
Earnings per share $1,111.96 $2,240.34 $3,236.60 $631.39 -$456.12 $864.45
Free cash flow $40.2M $51.9M $87.2M $77.7M $149.7M $93.9M
Free cash margin 11% 8% 11% 12% 24% 13%
Cash $717.3M $603.8M $523.5M $751.3M $757.4M $566.0M
Long-term debt $287.5M — — — $525.6M $542.2M
Shareholders' equity $1.5B $1.8B $1.9B $2.0B $2.0B $2.1B
Shares outstanding 54.76m 55.32m 55.56m 55.77m 56.09m 56.33m

Filings

SEC EDGAR
FiledReportPeriod to Lag
Oct 30, 2026 Quarterly ↗ Sep 30, 2026 30d
Jul 29, 2026 Quarterly ↗ Jun 30, 2026 29d
May 6, 2026 Quarterly ↗ Mar 31, 2026 36d
Feb 26, 2026 Annual ↗ Dec 31, 2025 57d
Nov 4, 2025 Quarterly ↗ Sep 30, 2025 35d
Aug 7, 2025 Quarterly ↗ Jun 30, 2025 38d
Apr 29, 2025 Quarterly ↗ Mar 31, 2025 29d
Mar 14, 2025 Annual ↗ Dec 31, 2024 73d
Nov 18, 2024 Quarterly ↗ Sep 30, 2024 49d
Jul 30, 2024 Quarterly ↗ Jun 30, 2024 30d
May 1, 2024 Quarterly ↗ Mar 31, 2024 31d
Feb 22, 2024 Annual ↗ Dec 31, 2023 53d

Current reports

FiledDisclosed
Oct 30, 2026 Unregistered share sale · Other events ↗
Oct 27, 2026 Results ↗
Oct 6, 2026 Acquisition or disposal · Regulation FD ↗
Sep 15, 2026 Director or officer change ↗
Sep 8, 2026 Other events ↗
Jul 28, 2026 Results ↗
Jul 22, 2026 Material agreement · Results · Regulation FD · Other events ↗
May 15, 2026 Shareholder vote ↗
May 5, 2026 Results ↗
Feb 24, 2026 Results ↗
Jan 6, 2026 Director or officer change · Regulation FD ↗
Oct 28, 2025 Results ↗